NCT00630994View on ClinicalTrials.gov

Low-Dose Decitabine in Treating Patients With Symptomatic Myelofibrosis

PHASE2TerminatedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

March 31, 2008

Primary Completion Date

August 31, 2009

Study Completion Date

April 30, 2012

Conditions
Chronic Myeloproliferative DisordersSecondary Myelofibrosis
Interventions
DRUG

Dacogen

Trial Locations (1)

55905

Mayo Clinic, Rochester

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Mayo Clinic

OTHER

NCT00630994 - Low-Dose Decitabine in Treating Patients With Symptomatic Myelofibrosis | Biotech Hunter | Biotech Hunter